Up-regulation of retinoic acid receptor β expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-α- 2a

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1671-1675

  Berg, William J ^a,c   Nanus, David M ^a,b,c,e   Leung, Abraham ^a,b   Brown, Karen T ^b   Hutchinson, Brian ^b   Mazumdar, Madhu ^b   Xu, Xiao Chun ^d   Lotan, Reuben ^d   Reuter, Victor E ^b   Motzer, Robert J ^a,c  

^a Genitourinary Oncology Service   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RECEPTOR SUBTYPE; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IN SITU HYBRIDIZATION; KIDNEY BIOPSY; KIDNEY CARCINOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

BIOPSY; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; INTERFERON-ALPHA; ISOTRETINOIN; KIDNEY NEOPLASMS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; UP-REGULATION;

EID: 0032765870     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Motzer, R. J., Schwartz, P., Murray-Law, T., Hoffman, A. D., Albino, A. P., Vlamis, V., and Nanus, D. M. Antitumor effects of interferon α-2a and 13-cis-retinoic acid in renal cell carcinoma: results of a Phase II trial and in vitro studies. J. Clin. Oncol., 13: 1950-1957, 1995.
3. Minasian, L. M., Motzer, R. J., Gluck, L., Mazumdar, M., Vlamis, V., and Krown, S. E. Interferon-α-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol., 11: 1368-1375, 1993.
4. Berg, W. J., Schwartz, L. H., Amsterdam, A., Mazumdar, M., Murray-Law, T., Vlamis, V., Nanus, D. M., and Motzer, R. J. Clinical studies with 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest. New Drugs, 15: 353-355, 1997.
5. Hoffman, A. D., Engelstein, D., Steckelman, E., Bogenrieder, T., Dave, A., Papandreou, C. N., Motzer, R. J., Albino, A. P., and Nanus, D. M. Expression of retinoic acid receptor β in human renal cell carcinomas correlates with sensitivity to the antiproliferative effect of 13-cis-retinoic acid. Clin. Cancer Res., 2: 1077-1082, 1996.
6. Collins, S. J., Robertson, K. A., and Muellar, L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-α). Mol. Cell. Biol., 10: 2154-2163, 1990.
7. Geradts, J., Chen, J. Y., Russell, E. K., Yankaskas, J. R., Nieves, L., and Minna, J. D. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ., 4: 799-809, 1993.
8. Swisshelm, K., Ryan, K., Lee, X., Tsou, H. C., Peacocke, M., and Sager, R. Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ., 5: 133-141, 1994.
9. Moasser, M. M., DeBlasio, A., and Dmitrovsky, E. Response and resistance to retinoic acid are mediated through the retinoic acid receptor in human teratocarcinomas. Oncogene, 9: 833-840, 1994.
10. Lotan, R., Xu, X. C., Lippman, S. M., Ro, J. Y., Lee, J. S., Lee, J. J., and Hong, W. K. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isoretinoin. N. Engl. J. Med., 332: 1405-1410, 1995.
11. Xu, X. C., Clifford, J., Hong, W., and Lotan, R. Detection of nuclear retinoic acid receptor mRNA in histological tissue sections using nonradioactive in situ hybridization histochemistry. Diagn. Mol. Pathol., 3: 122-131, 1994.
12. Anonymous. Practical Nonparametric Statistics. New York: John Wiley & Sons, 1980.
13. StatXact-Turbo. Cambridge, MA: CYTEL Software Corporation, 1991.
14. Lotan, R., Dawson, M. I., Zou, C. C., Jong, L., Lotan, D., and Zou, C. P. Enhanced efficacy of combinations of retinoic acid-and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res., 55: 232-236, 1995.
15. Lancillotti, F., Glandomenico, V., Affabris, E., Fiorucci, G., Romeo, G., and Rossi, G. B. Interferon α-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res., 55: 3158-3164, 1995.
16. Matikainen, S., Ronni, T., Hurme, M., Pine, R., and Julkunen, I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood, 88: 114-123, 1996.
17. Giandomenico, V., Lancillotti, F., Fiorucci, G., Percario, Z. A., Rivabene, R., Malorni, W., Affabris, E., and Romeo, G. Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1-and TGase II-dependent pathways. Cell Growth Differ., 8: 91-100, 1997.
18. Hong, W. K., Lippman, S. M., Hittelman, W. N., and Lotan, R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin. Cancer Res., 1: 677-686, 1995.
19. Lippman, S. M., and Davies, P. J. Retinoids, neoplasia and differentiation therapy. Cancer Chemother. Biol. Response Modif., 17: 349-362, 1997.